The European Medicines
Agency (EMA) has approved
Bayer’s Adempas (riociguat) in
the European Union for treatment
of chronic thromboembolic
(CTEPH) and pulmonary arterial
hypertension (PAH).The above snippet is the first part of an article sent to subscribers in Pharmacy Daily's issue from 03 Apr 14 To see the full story, see the embedded issue below or CLICK HERE to download Pharmacy Daily from 03 Apr 14
PROMPTED by yet another emergency situation threatening medicines access for patients, namely the tragic Townsville floods, the Pharmacy Guild of Australia has called for three key changes around medicines supply to consumers.